Nonsquamous Nonsmall Cell Neoplasm of Lung clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).
Irvine, California and other locations